OmicsMab™ Proteome Scale Antibody Discovery Services
Background Services Service Advantages FAQ Contact
In order to solve the current challenges of low throughput and high cost in antibody development, Creative Biolabs provides cost-effective OmicsMab™ proteome scale antibody discovery services to accelerate your antibody development through advanced proteomic analysis and high-throughput screening technologies.
Antibody Development is Undergoing Rapid Evolution
Antibody development continues to advance at an accelerated pace, driven by growing demands for targeting intricate proteomic structures in both therapeutic interventions and diagnostic methodologies. Conventional discovery techniques increasingly reveal limitations in achieving the necessary scope and precision required for complete proteome profiling. Recent advancements demonstrate that proteome-wide screening at high throughput capacities has become critical for isolating antibodies with superior functional characteristics and binding specificity - a breakthrough enabling systematic interrogation of vast antibody repositories to uncover scarce, high-potential therapeutic candidates.
Fig.1 Therapeutic antibodies development technologies.1
OmicsMab™ Proteome Scale Antibody Discovery Services at Creative Biolabs
Creative Biolabs provides comprehensive proteome-scale antibody discovery services that can deeply analyze antibody libraries against complex proteome targets. Our services provide detailed insights into antibody specificity, affinity, and functionality across the entire proteome, thereby facilitating the screening of high-quality candidate antibodies. Through our services, it is expected that your research process for therapeutic antibodies or antibody-related drugs will be accelerated. By integrating advanced technologies, we have developed a variety of customized services to meet the different needs of global customers, including:
High-Throughput Monoclonal Antibody Discovery Service
Our service streamlines antibody generation by leveraging a pre-validated library of antibodies against universal epitope tags. This platform enables researchers to rapidly access a versatile, high-throughput system applicable across all species, significantly reducing costs and time while maintaining high reproducibility.
Fast-Track Peptide-Specific Antibody Development Service
Leverage expert-guided peptide design coupled with precision chemical synthesis, stable carrier protein conjugation, and advanced immunization protocols. Our platform integrates hybridoma generation and phage display screening to identify high-affinity candidates. Every antibody undergoes stringent, application-tailored validation to guarantee target specificity and binding performance.
High-Density Antibody Profiling Service
Our profiling service enables proteomic-level analysis of antibody repertoires, moving beyond conventional binding assays to map specificity, cross-reactivity, and functional activity. By combining optimized sample processing, high-throughput screening, rigorous validation, and AI-driven analytics, our tailored workflow accelerates the identification of high-performance antibodies within a streamlined 10-18 weeks timeline.
Service Advantages
- Comprehensive Proteome Analysis
- Expedited Therapeutic Development
- Bespoke Solution Design
- Next-Generation Technology Integration
Frequently Asked Questions
Q1: How do you ensure comprehensive proteomic coverage?
A1: Our dual approach combines optimized proteomic library preparation with high-density antibody arrays, systematically mapping target protein landscapes. We'll tailor the workflow to your experimental objectives - share your project parameters for a customized solution.
Q2: Can you handle large and complex proteomic targets?
A2: Our automated screening platforms specialize in complex proteome characterization, delivering reproducible profiling data sets even for multi-domain protein systems and large-scale target panels.
Q3: What types of functional assays do you offer?
A3: Our functional characterization suite includes:
- Live-cell interaction profiling
- Quantitative binding kinetics
- Structure-function correlation analyses
Q4: How do your services compare to traditional antibody discovery methods?
A4: Next-generation proteomic screening accelerates discovery workflows, providing complete epitope mapping data in 30-40% less time than conventional hybridoma approaches while maintaining >98% specificity.
Q5: What format do you provide your data in?
A5: Deliverables include raw mass spec files, processed abundance matrices, and interactive visualization packages. We validate format compatibility with your analysis pipeline during project scoping.
Partner with Creative Biolabs
At Creative Biolabs, we combine cutting-edge proteomic technologies with deep antibody engineering expertise to provide comprehensive large-scale antibody discovery solutions. Our systematic screening platform identifies high-potential therapeutic candidates while streamlining therapeutic development timelines. If you are looking for a reliable partner to accelerate your antibody development projects, please feel free to contact us for further discussion.
Reference
- Lu, Ruei-Min, et al. "Development of therapeutic antibodies for the treatment of diseases." Journal of biomedical science 27 (2020): 1-30. Distributed under Open Access License CC BY 4.0, without modification.
For research use only. Not intended for any clinical use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
